Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Marina Biotech has completed dosing of second cohort in the Dose Escalation Phase of its Safety and Tolerability of An RNAi Therapeutic in Familial Adenomatous Polyposis (START-FAP) trial with CEQ508.
Subscribe to our email newsletter
The three patients of cohort 2 received a dose of 1×10(9) colony forming units (cfu)/day for up to 28 days of continuous oral dosing.
Dosing of third cohort is expected to commence in the second quarter of 2012 with each patient in the cohort receiving a dose of 1×10(10) cfu/day for up to 28 days.
Marina Biotech president and CEO Michael French said progression through the dose escalation phase will determine the most appropriate once-daily dose for the stable dose phase.
"We believe CEQ508 has the potential to be a safe and efficacious therapeutic for a patient population with no currently approved pharmaceutical alternative," French added.